Sigachi Industries SIGACHI

Summary

Sigachi is the larger of the two listed Indian excipient producers, with roughly 21,700 MTPA of microcrystalline cellulose capacity across Telangana and Gujarat and an export book that ran near 60% of sales. Through FY25 it was the sector's growth story, compounding revenue from about Rs 250 crore in FY22 to Rs 488 crore in FY25 at consistently ~20% operating margins.

Two things then happened. The company diversified away from its niche — into active pharmaceutical ingredients, operations-and-management services and allied trading — taking MCC from about 81% of revenue in Q2 FY25 to roughly 60% a year later. And on 30 June 2025 a fire and blast destroyed part of the Pashamylaram unit near Hyderabad, causing multiple fatalities. FY26 revenue finished at Rs 478 crore, down 2%, margin more than halved to 11%, and a consolidated net loss of about Rs 110 crore after an exceptional charge of roughly Rs 121 crore.

Management guides FY27 revenue of Rs 650–675 crore at an 18–20% EBITDA margin. We model Rs 600 crore at 15%, because Q1 FY27 annualises closer to Rs 485 crore and the guidance requires a steep second-half ramp. Two further facts drive our rating. On 22 August 2026 the board approved a preferential issue of up to 11 crore convertible warrants at Rs 26.40 — roughly 29% dilution at a 30% discount to the market, with 7.5 crore earmarked for the promoter, subject to an EGM on 15 September 2026. And the criminal file arising from the June 2025 incident remains open, with the Managing Director and Chief Executive Officer personally named. Our target price of Rs 31 — 24x fully diluted FY28E EPS of Rs 1.30 — implies 18% downside. We initiate with a SELL.

The structural point. The excipient moat is the customer's unwillingness to restart a three-to-five-year qualification clock — and that protection is symmetrical. A customer forced to qualify an alternative source during an interruption now has a switching cost that protects the replacement. Rebuilding a plant is faster than rebuilding a qualified customer book, and that asymmetry is the central uncertainty here.

• The asset base and the franchise are intact. Roughly 21,700 MTPA of MCC capacity, plants at Dahej and Jhagadia that absorbed production when Pashamylaram went down, a real export book and a thirty-five-year operating history. The FY25 numbers — Rs 488 crore at a ~20% operating margin — are evidence of what this business earns when it runs normally, and that is a genuinely good excipient business.
• The margin recovery has begun and is visible quarter by quarter. EBITDA margin bottomed at 6.8% in Q2 FY26, recovered to 7.5% in Q3, 12.6% in Q4 and approximately 13.5% in Q1 FY27. That is a coherent sequence rather than a single good quarter, and it is the strongest argument for the stock.
• Capacity and product-mix optionality. A 12,000 MT MCC expansion is targeted for Q4 FY27, and management has pointed to a complex fluorinated API portfolio with potential annual revenue of around Rs 250 crore from the same quarter. If both land, FY29 looks very different from FY26. Neither is in our base case.
• Valuation is not demanding on normalised earnings. On the FY25 earnings base the stock would trade at roughly 20x. The question is not whether Sigachi can earn Rs 70 crore again; it is when, and what share count and balance sheet it gets there with.

Source: Company filings and exchange disclosures. Margins are EBITDA before exceptional items.

Source: Company investor presentations and filings; Dart Consultants estimates for FY27E–FY28E. Segment shares are for the September quarter of each year.

• Guidance requires a ramp the run-rate does not yet support. Q1 FY27 revenue of Rs 121 crore annualises to about Rs 485 crore against guidance of Rs 650–675 crore. Reaching the low end requires roughly Rs 530 crore over the remaining three quarters — a sequential step of more than 45% — with the 12,000 MT expansion arriving only in Q4. Our Rs 600 crore estimate already assumes meaningful improvement; we would rather be raised to guidance than cut to reality.
• Diversification has diluted the moat. API manufacture, operations-and-management services and allied trading are competed against different firms, carry different risk, and do not benefit from the excipient qualification barrier. MCC falling from 81% to 60% of revenue is not obviously progress in a business whose only durable advantage is depth inside one qualified niche.
• Funding and governance flags. On the Q3 FY26 call, management was pressed on a reported shortfall of approximately Rs 68.6 crore from warrant holders and around Rs 56.8 crore in promoter investment commitments. Promoter holding stands near 36.7%, low for a company undertaking a large capital programme. Screening services also flag an unusually low effective tax rate. Individually explicable; collectively they justify a higher required return.
• Qualified customers may not return. This is the risk the market is least able to observe. Customers who re-qualified an alternative source during the outage face a switching cost to come back. Recovery of revenue is therefore not the same as recovery of margin — replacement volume may be lower-specification or food-grade. Watch MCC's share of revenue and blended realisation, not the headline top line.
• The rating has re-rated ahead of the recovery. The stock is up roughly 180% from its low on 5.8% return on equity and 64x trailing earnings. Even our FY28E, which assumes a successful ramp, leaves the shares on 25x earnings and 12x EV/EBITDA — full for a business two years from proving it has normalised.

This section deals with an ongoing criminal investigation and unresolved litigation arising from an industrial accident in which many people died. We report only what has been publicly stated by the company, by government representatives in open court, or in mainstream press coverage. Nothing here has been adjudicated; all parties are entitled to the presumption of innocence. We include it because it is material to the security, not to apportion blame.

Developments that would move our view

• The 15 September 2026 EGM and, more importantly, actual conversion of the warrants. The 2023 precedent means allotment and capital receipt are not the same event.
• Quarterly revenue and margin trajectory. Q1 FY27 revenue of Rs 121 crore annualises to about Rs 485 crore against guidance of Rs 650–675 crore. Reaching the low end needs roughly Rs 530 crore across the remaining three quarters.
• MCC as a share of revenue. A recovery toward 75% or more would indicate the core franchise is being rebuilt rather than replaced by lower-quality volume.
• The 12,000 MT expansion and first revenue from the complex fluorinated API portfolio, both indicated for Q4 FY27.
• Legal milestones — chargesheet, framing of charges, High Court directions on compensation, and the outcome of the pending public interest litigation.
• Insurance settlement against the Rs 121 crore exceptional charge.
• Any disclosure of an independent safety audit or restart certification at the affected site.

Key risks to be aware of

• Legal and regulatory risk — the dominant one. Criminal proceedings arising from the incident are unresolved, the chief executive has been reported as arrested, and the final compensation liability is not yet fixed. Outcomes range from immaterial to severe, and an investor cannot currently price them.
• Dilution risk. Up to 11 crore warrants at Rs 26.40 would dilute existing holders by roughly 29% at a price about 30% below the market.
• Customer-recovery risk. Rebuilding a qualified customer book is slower than rebuilding a plant, and returning revenue may carry lower specification and lower margin than the revenue it replaces.
• Guidance risk. Management's FY27 revenue and 18–20% margin guidance requires a step-change the current run-rate does not yet evidence.
• Reputational risk in regulated markets. Pharmaceutical customers audit suppliers on environment, health and safety. An unresolved fatal-incident file is a live issue in those audits.
• Concentration of strategic control. A promoter at 36.7% rebuilding stake to 43.73% through a discounted issue, while personally named in proceedings, concentrates both control and risk.
• Valuation risk. Even before dilution, the shares trade on roughly 64x trailing earnings after a rise of about 180% from the 52-week low.

Source: Dart Consultants estimates. Diluted share count assumes full conversion of the proposed 11 crore warrants; diluted PAT adds an estimated post-tax interest saving from deploying part of the proceeds against debt. The base multiple is set below the undiluted case to reflect the governance overhang.

Source: Company annual reports, investor presentations, quarterly filings and CARE Ratings for FY22–FY26; Dart Consultants estimates for FY27E–FY28E. Items marked "~" are derived from disclosed aggregates rather than reported separately. FY26 is materially affected by the exceptional charge relating to the Pashamylaram incident.

Source: Company annual report FY24, investor presentations, CARE Ratings press release of January 2025, and public market aggregators as at September 2026. Dashes indicate not separately disclosed. As with Accent, we have restricted this table to sourced or directly derivable figures rather than modelling a full balance sheet.